Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.200-2.500 for the period, compared to the consensus estimate of 2.410. The company issued revenue guidance of $15.7 billion-$16.3 billion, compared to the consensus revenue estimate of $15.9 billion.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on TEVA. Jefferies Financial Group raised Teva Pharmaceutical Industries from a hold rating to a buy rating and increased their price target for the stock from $10.00 to $14.00 in a research report on Tuesday, January 23rd. The Goldman Sachs Group upped their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a neutral rating in a research report on Monday, February 5th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a buy rating to a strong-buy rating in a research note on Thursday, February 1st. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a neutral rating to an overweight rating and boosted their target price for the company from $12.00 to $19.00 in a research report on Monday, February 12th. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an underweight rating to a neutral rating and set a $14.00 price target on the stock in a research report on Friday, March 8th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of Moderate Buy and a consensus target price of $13.78.
Check Out Our Latest Stock Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Price Performance
TEVA stock traded up $1.78 during trading on Wednesday, reaching $15.74. 38,496,364 shares of the company were exchanged, compared to its average volume of 10,795,424. The company has a market capitalization of $17.64 billion, a price-to-earnings ratio of -33.48, a P/E/G ratio of 1.67 and a beta of 1.04. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69. The company has a 50-day moving average of $13.70 and a two-hundred day moving average of $11.72. Teva Pharmaceutical Industries has a twelve month low of $7.09 and a twelve month high of $16.13.
Insider Activity
In other Teva Pharmaceutical Industries news, CEO Richard D. Francis sold 74,530 shares of the company's stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $13.15, for a total value of $980,069.50. Following the completion of the transaction, the chief executive officer now owns 87,125 shares of the company's stock, valued at approximately $1,145,693.75. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Teva Pharmaceutical Industries news, CEO Richard D. Francis sold 74,530 shares of the business's stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the sale, the chief executive officer now directly owns 87,125 shares of the company's stock, valued at approximately $1,145,693.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mark Sabag sold 100,000 shares of the company's stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the transaction, the executive vice president now owns 382,590 shares of the company's stock, valued at $5,172,616.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 358,972 shares of company stock worth $4,739,820. Insiders own 0.55% of the company's stock.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Further Reading
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
